Monday, October 26, 2026 · Daily editionET --:--:--

Finished

Rehabilitative Effect of the Use of a Gait Exoskeleton in Patients With Neuromuscular Disease or Cerebral Palsy

NCT04813601 · MarsiBionics · Updated 26 Oct 2023

What is being tested
ATLAS 2030
For
Neuromuscular Diseases; Cerebral Palsy; SMA II
Kind of study
Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
Who can join
Ages 3 years to 14 years. About 10 people. The full rules are on the registry page.
Where
Spain
When
Starts or started 9 March 2020, ends 24 Sept 2023. Registered 24 March 2021.
Results
None posted yet.

In the researchers' words

The purpose of this multicentric study is to assess the rehabilitative effect derived from the use of the ATLAS exoskeleton in children with neuromuscular diseases or cerebral palsy and with a level of less than 3 or less in the Functional Ambulation Classification (FAC) as a consequence of their disease, as well as the assessment of other physical, functional and quality of life parameters of interest. For this purpose, the exoskeleton will be used as a rehabilitation and walking assistance tool. Before starting the study programme and if deemed necessary, a preliminary phase consisting of 1 to 3 sessions will be carried out during which the patient will be shown the exoskeleton for the first time and it will be considered whether any improvements to the different parts of the device or the software are necessary to increase the ergonomics and comfort of the patient.
ClinicalTrials.gov, NCT04813601

Sites

  • MarsiCareArganda, Madrid, Spain